The Global Griseofulvin (CAS 126-07-8) Market was valued at USD 215.4 Million in 2025 and is projected to reach USD 342.8 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 5.4% during the forecast period. This growth is being driven by the persistent prevalence of dermatophyte infections, rising demand in pediatric dermatology, and the cost-effectiveness of griseofulvin as a first-line treatment for superficial fungal conditions across global healthcare systems.

As the pharmaceutical industry continues to address the widespread burden of fungal infections affecting millions worldwide, the spotlight is on the key manufacturers and suppliers who are driving production efficiency, formulation advancements, and reliable supply of this essential antifungal agent. In this blog, we profile the Top 10 Companies in the Griseofulvin (CAS 126-07-8) Market—a mix of generic giants, API specialists, and regional producers shaping the future of antifungal therapeutics.

---

🔟 1. Teva Pharmaceutical Industries Ltd.

Headquarters: Tel Aviv, Israel
Key Offering: Griseofulvin Tablets, Oral Suspension, and API

Teva is a global leader in generic pharmaceuticals and a major supplier of griseofulvin formulations. The company leverages its extensive manufacturing network to provide high-quality antifungal medications serving hospitals, clinics, and retail pharmacies worldwide, with strong emphasis on pediatric applications.

Key Initiatives:

• Expansion of generic antifungal portfolio

• Focus on bioequivalent formulations for improved bioavailability

• Global supply chain optimization for consistent API availability

Download FREE Sample Report: Griseofulvin (CAS 126-07-8) Market – View in Detailed Research Report

---

9️⃣ 2. Lupin Limited

Headquarters: Mumbai, India
Key Offering: Griseofulvin API and Finished Dosage Forms

Lupin is a prominent player in the antifungal segment with robust capabilities in fermentation-based API production. The company supplies griseofulvin to both domestic and international markets, supporting treatment of tinea infections in emerging economies.

Key Initiatives:

• Investment in high-purity API manufacturing

• Partnerships for distribution in high-burden regions

---

8️⃣ 3. Aurobindo Pharma

Headquarters: Hyderabad, India
Key Offering: Griseofulvin Tablets and Ultramicrosize Formulations

Aurobindo has established itself as a reliable producer of cost-effective griseofulvin products. Its vertically integrated operations enable competitive pricing while maintaining regulatory compliance across multiple markets.

Key Initiatives:

• Scale-up of micronized particle technologies

• Expansion into veterinary antifungal applications

---

7️⃣ 4. Viatris Inc.

Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Generic Griseofulvin Oral Products

Viatris delivers essential medicines including griseofulvin to healthcare providers globally. The company focuses on accessibility and quality in antifungal treatments for diverse patient populations.

Key Initiatives:

• Portfolio enhancement for dermatological generics

• Commitment to supply stability in critical medicines

Download FREE Sample Report: Griseofulvin (CAS 126-07-8) Market – View in Detailed Research Report

---

6️⃣ 5. Sandoz International GmbH

Headquarters: Holzkirchen, Germany
Key Offering: Griseofulvin Generic Formulations

As a division of Novartis, Sandoz provides affordable griseofulvin options across Europe and other regions. The company emphasizes rigorous quality standards and patient-centric antifungal solutions.

Key Initiatives:

• Development of patient-friendly dosage options

• Regulatory compliance and pharmacovigilance excellence

---

5️⃣ 6. Dr. Reddy’s Laboratories

Headquarters: Hyderabad, India
Key Offering: Griseofulvin API and Dosage Forms

Dr. Reddy’s is a key contributor to the global supply of griseofulvin, known for its research-driven approach and efficient production processes that support both human and veterinary needs.

Key Initiatives:

• Advancements in formulation stability

• Focus on markets with high fungal disease prevalence

---

4️⃣ 7. Shandong Xinhua Pharmaceutical Co., Ltd.

Headquarters: Zibo, China
Key Offering: Griseofulvin API

Shandong Xinhua is a significant API manufacturer supplying griseofulvin to formulators worldwide. The company maintains large-scale production facilities compliant with international standards.

Key Initiatives:

• Capacity expansion for antifungal intermediates

• Quality assurance programs for export markets

---

3️⃣ 8. Jiangxi Fushine Pharmaceutical Co., Ltd.

Headquarters: Jiangxi, China
Key Offering: High-Purity Griseofulvin API

Fushine specializes in pharmaceutical intermediates and APIs, including griseofulvin, serving global clients with reliable and cost-competitive products.

Key Initiatives:

• cGMP-compliant manufacturing upgrades

• Custom synthesis capabilities

Download FREE Sample Report: Griseofulvin (CAS 126-07-8) Market – View in Detailed Research Report

---

2️⃣ 9. Perrigo Company plc

Headquarters: Dublin, Ireland
Key Offering: OTC and Generic Griseofulvin Products

Perrigo focuses on consumer healthcare and generic pharmaceuticals, making griseofulvin accessible through various distribution channels for dermatological care.

Key Initiatives:

• Consumer education on fungal infection management

• Portfolio diversification in dermatology

---

1️⃣ 10. Megafine Pharma (P) Ltd.

Headquarters: Vadodara, India
Key Offering: Specialty Griseofulvin API and Intermediates

Megafine excels in custom manufacturing and high-quality API production for niche antifungal requirements, supporting specialized therapeutic needs.

Key Initiatives:

• Innovation in particle size engineering

• Strategic collaborations with global formulators

Get Full Report Here: Griseofulvin (CAS 126-07-8) Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Griseofulvin Market Is Accessible and Reliable

The griseofulvin market continues to evolve steadily. While newer antifungals gain attention, this established agent maintains its position due to proven efficacy, affordability, and specific utility in pediatric and certain resistant cases.

📈 Key Trends Shaping the Market:

• Growing demand in emerging markets with high fungal infection rates

• Advancements in micronized and ultramicronized formulations

• Expansion of veterinary applications for dermatophytosis

• Focus on supply chain resilience and API quality consistency

Get Full Report Here: Griseofulvin (CAS 126-07-8) Market – View in Detailed Research Report

The companies listed above are not only supplying essential antifungal medication—they’re ensuring continued access to effective treatments for dermatophyte infections worldwide.